Chemical Resources – Trademark Portfolio

Entity Type: 19

Chemical Resources holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include FENFURO, RHIZOMK, FUROCYST, and CHEMFORCE. The owner is based in Panchkula.

SCO 76, 1st floor, Swastik Vihar

SCO 76, 1st floor, Swastik Vihar

Panchkula 134112 , IN

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

RHIZOMK
RHIZOMK
Registered 2018
FENFURO
FENFURO
Registered 2018
FUROCYST
FUROCYST
Registered 2018
CHEMFORCE
CHEMFORCE
Registered 2018
FUROSAP
FUROSAP
Abandoned 2018
PROSMAN
PROSMAN
Abandoned 2018

Trademark Classifications

Chemical Resources's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Chemical Resources have?

Chemical Resources has 6 U.S. trademarks filed with the USPTO. Of these, 4 registered, 2 abandoned.

What trademark classes does Chemical Resources file in?

Chemical Resources files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Chemical Resources's most well-known trademarks?

Chemical Resources's registered trademark portfolio includes well-known marks such as FENFURO, RHIZOMK, FUROCYST, and CHEMFORCE. These are among 4 currently registered trademarks in the portfolio.

What is Chemical Resources's trademark registration success rate?

Chemical Resources has a 67% trademark registration rate, with 4 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.